Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Valneva SE
Less than a year after signing a major advance purchase agreement to supply its inactivated COVID-19 jab to the EU, Valneva is faced with a termination that could hit its 2022 guidance.
In exploratory FDA analyses, PRO data appeared more sensitive at detecting an exposure-toxicity relationship for an oral small molecule cancer drug than clinician-reported data; Project Optimus representative dispels industry concerns that FDA wants firms to find the 'mythical' optimal dose.
Also, Cytovia will go public via SPAC merger, Nkarta capitalized on its positive early NK cell therapy data with a $230m offering, and venture capital mega-rounds include $220m for Reify, $110m for Satellite Bio and $100m for OMass Therapeutics.
The MHRA has become the first regulatory agency worldwide to grant a marketing authorization for the inactivated whole virus COVID-19 vaccine, VLA2001.
- Contract Research, Toxicology Testing-CRO
- Drug Delivery
- Drug Discovery Tools
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- BliNK Biomedical SAS
- Crucell Sweden AB
- Iomai Corporation
- Intercell USA, Inc.
- Intercell AG, Vivalis